<DOC>
	<DOCNO>NCT01598831</DOCNO>
	<brief_summary>The purpose study evaluate ART-123 give patient severe sepsis decrease mortality .</brief_summary>
	<brief_title>Phase 3 Safety Efficacy Study ART-123 Subjects With Severe Sepsis Coagulopathy</brief_title>
	<detailed_description>Study evaluate ART-123 give patient severe sepsis complicate least one organ dysfunction coagulopathy decrease mortality .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Subject must receive treatment ICU , acute care set ( e.g. , ER , RR ) Clinical objective evidence bacterial infection know site infection . Cardiovascular dysfunction Respiratory Failure due sepsis . Coagulopathy characterize INR &gt; 1.40 without know cause . Subject Authorized Representative unable provide inform consent . Subject pregnant breastfeeding intend get pregnant within 28 day enrol study . Subject childbearing potential negative pregnancy test . Subject &lt; 18 year age . Subject know allergy ART123 component drug product . Subject unwilling allow transfusion blood blood product . Subject advance directive withhold lifesustaining treatment . Subject previous treatment ART123 . Body weight â‰¥ 175 kg . Platelets &lt; 30,000/ mm3 reason , PT prolongation thrombocytopenia due sepsis . Any surgery potentially hemorrhagic ( e.g . intrathoracic , intraabdominal nontraumatic orthopedic surgery femur pelvis ) complete within 12 hour prior first dose study drug , ongoing impairment hemostasis result one procedures History head trauma , spinal trauma , acute trauma increase risk bleeding within 3 month prior consent . Cerebral Vascular Accident ( CVA ) within 3 month prior consent . Any history intracerebral arteriovenous malformation ( AVM ) , cerebral aneurysm , mass lesion central nervous system . History congenital bleeding diathesesor anatomical anomaly predisposes hemorrhage ( e.g . hemophilia , hereditary hemorrhagic telangiectasia ) . Significant gastrointestinal bleeding within 6 week prior consent . Subject diagnose know medical condition associate hypercoagulable state . ChildPugh score 1015 ( Class C ) Portosystemic hypertension know history bleed esophageal varix . History solid organ , allogeneic bone marrow , stem cell transplantation within 6 month prior consent . Acute pancreatitis infection document positive blood abdominal fluid culture gram stain consistent bacterial infection . Subjects renal dysfunction define ( ) Chronic renal failure require renal replacement therapy ( RRT ) , ( b ) Acute renal failure onset oliguria ( urine output &lt; 0.3 ml/kg/hr ) &gt; 48 hour prior first dose study drug whether receive RRT Use anticoagulant , antiplatelet agent , antithrombotics thrombolytic within 72 hour prior first study drug . Life expectancy &lt; 90 day . Current use chemotherapy agent likely cause myeloablation ( severe complete depletion bone marrow ) . Participation another research study involve investigational agent within 30 day prior consent project study participation 28 day post study randomization . Confirmed suspect endocarditis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>sepsis</keyword>
</DOC>